Latest Updates

With 2020 state legislative sessions in full swing (39 state legislatures in session this week), issues like drug pricing, pharmacy Medicaid reimbursement, pharmacist scope of practice and PBM transparency are being debated in statehouses across the country.

Last week, the National Community Pharmacists Association (NCPA) shared a new study published by XIL Consulting showing how DIR fees charged by PBMs are negatively impacting pharmacies and patients.

In the press release below, NCPA highlights a recent analysis illustrating PBMs’ enormous profits at the expense of pharmacies and patients.

Asking Virginia Pharmacists to please email and call your respective State Senators and Delegates and urge them to vote IN FAVOR of companion bills, HB 1506 and SB 1026. These two bills relate to the prescriptive authority of pharmacists under statewide protocols for critical medications including antibiotics, Tamiflu and hormonal contraceptives.

NCPA cheered the U.S. Supreme Court's decision to hear an Arkansas case to decide whether ERISA preempts (supersedes) a state law that regulates pharmacy benefit managers — massive corporate middlemen who have operated in a regulatory no-man's land for decades.